Article
Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.
Cancer reports (Hoboken, N.J.) - 1 Dec 2025
Maddula Meghana, Decaria Annelise, Brown Bea, Simes John, Boyer Michael, Chin Venessa
Abstract excerpt
BACKGROUND: Oncogene-driven metastatic non-small cell lung cancer (mNSCLC) is associated with poor survival outcomes, despite advancements in first-line tyrosine kinase inhibitor (TKI) therapies. AIMS: This study aimed to characterise second-line treatment strategies for epidermal growth factor receptor (EGFR)-driven mNSCLC, and to evaluate associated clinical outcomes using real-world data. MATERIALS: The EnRICH...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.